UNSPSC 51281628: Capreomycin

This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C19H30N12O6(R1)(R2), a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 232HYX66HC, more generally known as capreomycin. European Medicines Agency schedules capreomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01028MIG. The term CAPREOMYCIN is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19 1975, list 5.

UNSPSC 51281628 Capreomycin, a Commodity code, nominally covers a specific tuberculosis antibiotic; however, the recent state and local activity indexed under this code does not reflect purchases of capreomycin itself. Instead, the opportunities tagged to this code show state and local health and emergency-response agencies procuring a broader range of pharmaceutical and medical-response products — including antibiotics, opioid-reversal agents, and drug deactivation systems — through piggyback contracts and competitive bidding processes. The solicitations reflect health departments and county emergency services buying these products to support disease control, overdose response, and community health initiatives, typically through cooperative purchasing vehicles or direct IFB processes with terms of 12 to 36 months and options to renew.

Recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC (posted August 28, 2026; completed award) for doxycycline and ciprofloxacin tablets under an Invitation for Bid process, while Seminole County, Florida issued an IFB (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries, fixed-fee pricing, and a two-year initial term plus one-year renewal option. The mismatch between the code's nominal scope and the pharmaceutical products actually being bought suggests either broad tagging of pharmaceutical procurement across multiple antibiotic and emergency-response categories or a data-quality issue in the indexing; purchasers pursuing capreomycin specifically should verify code alignment before responding.